GlioPharma ApS: Financial statements 2018
CVR: 37256641
Source: annual report 2018, Danish Business Authority
01/05/2017 – 30/04/2018
GlioPharma ApS (CVR 37256641) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK -14,505 and a net result of DKK -21,600. Equity in the 2018 report amounted to DKK 32,817. The solvency ratio was 19.5%.
- Gross Profit
- DKK -14,505
- Profit/Loss
- DKK -21,600
- Equity
- DKK 32,817
- Total Assets
- DKK 168,718
- Employees
- 0
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2018
As of September 19, 2018, John Bo Jacobsen has stepped down as chairman of GlioPharma ApS.
About GlioPharma ApS
GlioPharma ApS was a Danish company of the type Anpartsselskab based in Kolding, founded in 2015. The company has been dissolved on 24 June 2019. The company was registered under the industry Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik. According to the 2018 annual report, the company had an average of 0 employees. In 2018, the company reported a gross profit of DKK -14,505 and a net result of DKK -21,600. Equity in the 2018 report amounted to DKK 32,817.